Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS

SOL686Paper
Written By James Cotton
James Cotton
Previous

S6K1 inhibitors for fragile X syndrome and triple negative breast cancer
Next

Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor